AI assistant
IMPEDIMED LIMITED — Earnings Release 2024
Aug 28, 2024
65135_rns_2024-08-28_3413a61c-45c0-4aa1-a5b0-04c44c1d38d4.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [230 x 54] intentionally omitted <==
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: [email protected] W : impedimed.com
29 August 2024
Companies Announcements Office Australian Securities Exchange
Appendix 4E – Financial year ended 30 June 2024
ImpediMed Limited (ASX: IPD) provides the attached Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2024.
Approved for release by the Board of ImpediMed Limited.
For more information, contact Leanne Ralph, Company Secretary, at [email protected]
Appendix 4E ImpediMed Limited ABN 65 089 705 144 Preliminary Final Report
| Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | Preliminary Final ReportImpediMed Limited ABN 65 089 705 144Appendix 4E | ||
|---|---|---|---|---|---|---|---|---|
| 12 | Reporting period:Year ended 30 June 2024Prior Corresponding Reporting Period:Year ended 30 June 2023Results for announcement to the market | |||||||
| % change$000Revenuedown-9%to10,319(Loss) from ordinary activities after taxattributable to membersdown-4%to-19,790(Loss) for the periodattributable to membersdown-4%to-19,790 | ||||||||
| , | ||||||||
| Dii | ||||||||
| Net tangible assets per security30-June-202430-June-2023Net tangible assets per security1.22 cents2.28 cents |
Additional Appendix 4E disclosure requirements are included in the 30 June 2024 Annual Financial Statements lodged with this document. The report is based on the 30 June 2024 Annual Financial Statements which are audited by Ernst & Young and are not subject to dispute, modification, or qualification.The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2024 and any public announcements made by ImpediMed Limited and its controlled entities during the year.